Zur Rolle kortikolimbischer affektregulatorischer Mechanismen bei der Therapie depressiver Erkrankungen

Zusammenfassung

Die Komplexität der affektiven Erkrankungen zugrunde liegenden Pathomechanismen erschwert den therapeutischen Zugang zu diesen Störungen. Während die medikamentöse Therapie depressiver Erkrankungen bisher hauptsächlich auf die Beeinflussung monoaminerger Neurotransmittersysteme zielte, mehren sich Hinweise, dass auch bisher weniger beachtete Regelkreise für die Affektregulation bei depressiven Störungen bedeutsam sind. Hierzu zählen insbesondere kortikolimbische, sog. top-down-Regulationsmechanismen, die bei depressiven Erkrankungen in engem Zusammenhang stehen mit negativen Prädiktionen und der damit verbundenen Beeinflussung der Wahrnehmung depressiver Menschen. Neuroanatomische und neurophysiologische Korrelate derartiger Prozesse konnten lange Zeit meist nur hypothesengeleitet beschrieben werden. Inzwischen bestätigen bildgebende Verfahren die Vermutung, dass top-down-Mechanismen bei der auf Vergangenheit und Erinnerung bezogenen Affektregulation depressiver Menschen beteiligt sind und dass sich diese auch durch psychotherapeutische Verfahren oder medikamentöse stimmungsstabilisierende Ansätze (wie z. B. die Augmentation mit Antikonvulsiva oder Neuroleptika der zweiten Generation) positiv beeinflussen lassen. Die Arbeit gibt einen kurzen Überblick über relevante Literatur und einen Ausblick auf die klinische Bedeutung der kortikolimbischen top-down-Regulation bei Depression.

Abstract

Complex functional mechanisms underlie the etiopathogenesis of affective disorders. However, therapeutic implications of new insights are still limited. From the neuropsychological perspective therapy focuses on limbic-cortical (bottom-up) processes whereas cortical-limbic regulatory systems (top-down) were rarely mentioned, although first evidence of their relevance was given in the 80ties, e. g. the use of GABAergic anticonvulsants in affective disorders. Meanwhile modern brain imaging studies support a pronounced role of cortical-limbic top-down mechanisms in the regulation of mood and the therapy of depression, e. g. the effects of cognitive behavioural therapy. The article briefly reviews relevant literature focusing on the neuropsychological hypothesis and the therapeutic implications of these and pharmacologic data. Psychotherapy as well as anticonvulsants appear to mainly affect cortico-limbic mechanisms compared to antidepressants which influence mostly limbic-cortical processes. The combination of both regulatory systems, e. g. the combination of antidepressants and anticonvulsants, appear to have synergistic effects. Such combinations may also be effective in low doses of each compound which does, furthermore, reduce the amount of unwanted side-effects. Studies combining classical antidepressants and mood-stabilizing medication (anticonvulsants and newer neuroleptics) should be performed to substantiate these findings.

Depression - Neuropsychologie - kortikolimbische Rückkoppelung - Top-down-Konzept der Affektregulation - Stimmungsstabilisierer

depression - neuropsychology - cortical-limbic pathways - top-down-concept of affect-regulation - mood-stabilizer

Literatur

• 1 Axelrod J. The metabolism, storage, and release of catecholamines.  Recent Prog Horm Res. 1965;  21 597-622
• 2 Schildkraut J J. The catecholamine hypothesis of affective disorders: a review of supporting evidence.  American Journal of Psychiatry. 1965;  122 509-522
• 3 Drevets W C. Neuroimaging studies of mood disorders.  Biol Psychiatry. 2000;  48 (8) 813-829
• 4 Manji H K, Drevets W C, Charney D S. The cellular neurobiology of depression.  Nature Medicine. 2001;  7 541-547
• 5 Bauer M. Behandlung der akuten Depression mit Lithium. In: Müller-Oerlinghausen B, Greil W, Berghöfer A (Hrsg) Die Lithiumtherapie. Berlin; Springer 1997: 178-189
• 6 Emrich H M, Zerssen D von, Kissling W, Möller H-J, Windorfer A. Effect of sodium valporate in mania. The GABA-hypothesis of affective disorders.  Arch Psychiat Nervenkr. 1980;  229 1-16
• 7 Emrich H M, Dose M, Zerssen D von. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders.  J Affect Dis. 1985;  8 243-250
• 8 Emrich H M, Dose M, Wolf R. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.  Neuropsychobiology. 1993;  27 158-162
• 9 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 (suppl 5) 51-59
• 10 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.  J Clin Psychiatry. 1999;  60 79-88
• 11 Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H. Modulation of cortical-limbic pathways in major depression; treatment-specific effects of cignitive behavior therapy.  Arch Gen Psychiatry. 2004;  61 (1) 34-41
• 12 Hasler G, van der Veen J W, Tumonis T, Meyers N, Shen J, Drevets W C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.  Arch Gen Psychiatry. 2007;  64 (2) 193-200
• 13 Sanacora G, Gueorguieva R, Epperson C N, Wu Y T, Appel M, Rothman D L, Krystal J H, Mason G F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.  Arch Gen Psychiatry. 2004;  61 705-713
• 14 Kandel E R. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited.  Am J Psychiatry. 1999;  156 505-524
• 15 Amaral D G, Price J L, Pitkanen A, Carmichael S T. Anatomical organization of the primate amygdaloid complex. In: Aggleton JP (ed). New York; Wiley 1992: 1-66
• 16 Rolls E T. A Theory of Emotion and Consciousness, and Its Application to Understanding the Neural Basis of Emotion. In: Gazzaniga MS (ed) The Cognitive Neurosciences. Cambridge; Bradford Book 1995: 1091-1106
• 17 Rolls E T. Neurophysiology and functions of the primate amygdala. In: Aggleton JP (ed) The amygdala: Neurobiological aspects of emotion, memory, and mental dysfunction. New York; Wiley-Liss 1992: 143-165
• 18 Canli T, Zhao Z, Brewer J, Gabriel J D, Cahill L. Event related activation in the human amygdala associates with later memory for individual emotional experience.  J Neurosci. 2000;  20 99
• 19 Desimone R, Miller E K, Chelazzi L, Lueschow A. Multiple Memory Systems in the Visual Cortex. In: Gazzaniga MS (ed) The Cognitive Neurosciences. Cambridge; Bradford Book 1995: 475-486
• 20 Kandel E R, Schwartz J H, Jessell T M. Neurowissenschaften. Heidelberg; Spektrum 1996: 622
• 21 Drevets W C. Neuroimaging abnormalities in the amygdala in mood disorders.  Ann NY Acad Sci. 2003;  985 420-444
• 22 Sapolsky R M. Atrophy of the hippocampus in posttraumatic stress disorder: how and when?.  Hippocampus. 1991;  11 90-91
• 23 Bremner J D, Narayan M, Anderson E R, Staib L H, Miller H L, Charney D S. Hippocampal volume reduction in major depression.  Am J Psychiatry. 2000;  147 115-118
• 24 Starkman M N, Giordani B, Gebarski S S, Berent S, Schork M A, Schteingart D E. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease.  Biol Psychiatry. 1999;  46 1595-1602
• 25 Dwivedi Y, Rizavi H S, Roberts R C, Conley R C, Tamminga C A, Pandey G N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects.  J Neurochem. 2001;  77 916-928
• 26 Stewart R J, Chen B, Dowlatshahi D, MacQueen G M, Young L T. Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium.  Brain Res Bull. 2001;  55 625-629
• 27 Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, Bartolomucci A, Fuchs E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine.  Proc Natl Acad Sci USA. 2001;  98 12796-12801
• 28 Schwartz J M, Stoessel P W, Baxter Jr L R, Martin K M, Phelps M E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder.  Archives of General Psychiatry. 1996;  53 109-113
• 29 Baer L. Behavior therapy: endogenous serotonin therapy?.  Journal of Clinical Psychiatry. 1996;  57 (Suppl 6) 33-35
• 30 Mumford D. On the computational architecture of the neocortex.  Biol Cybern. 1991;  65 135-145
• 31 Gray J A, Rawlins J NP. Comparator and buffer memory: An attempt to integrate two models of hippocampal function. In: Isaacson RL, Pribram KH (eds) The hippocampus, Vol. 4. New York; Plenum 1986: 159-201
• 32 Emrich H M, Dietrich D E. Das depressive Selbst, Neurobiologie und Schicksal: Betrachtungen anhand des Theaterstücks von Sarah Kane: „4.48 Psychose”.  Psychiat Prax. 2007;  34, Suppl 3 S243-S246
• 33 Wilensky A E, Schafe G E, Le Doux J E. The amygdala modulates memory consolidation of fear-motivated inhibitory avoidance learning but no classical fear conditioning.  J Neurosci. 2000;  20 7059-7066
• 34 Owens M J, Nemeroff C B. Pharmacology of valproate.  Psychopharmacol Bull. 2003;  37, Suppl 2 17-24
• 35 Dose M, Emrich H M. Antikonvulsiva in der Psychiatrie. Stuttgart; Kohlhammer 2000
• 36 Suppes T, Dennehy E B. Bipolar Disorder: The latest Assessment and Treatment Strategies. Compact Clinicals, Midpoint Trade Books Inc 2005
• 37 Woodman C L, Noyes R. Panic disorder: treatment with valproate.  J Clin Psychiatry. 1994;  55 134-136
• 38 Post R M, Uhde T W, Putnam F W. et al . Kindling and carbamazepine in affective illness.  J Nerv Ment Dis. 1982;  170 717-731
• 39 Emrich H M. Zur Neuropsychologie der Wahrnehmungs-Emotions-Kopplung. In: Förster CH, Merkenschlager A (Hrsg) Aktuelle Neuropädiatrie 1997. Nürnberg; Novartis Pharma Verlag 1998: 82-93
• 40 Gemar M C, Zindel V S, Mayberg H S, Goldapple M S, Carney C. Changes in regional cerebral blood flow following mood challenge in drug-free remitted patients with unipolar depression.  Depres Anxiety. 2006, Epub ahead of print;  , Nov 28 PMID: DOI: 17133439
• 41 Ehlis A C, Herrmann M J, Pauli P, Stoeber G, Pfuhlmann B, Fallgatter A J. Improvement of prefrontal brain function in endogenous psychoses under atypical antipsychotic treatment.  Neuropsychopharmacology. 2007;  32 1669-1677
• 42 McIntyre R S, Soczynska J K, Woldeyohannes H O, Alsuwaidan M, Konarski J Z. A preclinical and clinical rationale for quetiapine in mood syndromes.  Expert Opin Pharmacother. 2007;  8 (9) 1211-1219
• 43 Tyson P J, Roberts K H, Mortimer A M. Are the cognitive effexcts of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?.  Int J Neurosci. 2004;  114 593-611